Morgan Stanley analyst David Bailey initiated coverage of Fisher & Paykel Healthcare with an Equal Weight rating and NZ$36.30 price target A strong EPS outlook over the next three years is underpinned by new applications growth in the Hospital segment and recent obstructive sleep apnea mask launches, but the introduction of U.S. tariffs presents potential delays to margin targets, the analyst tells investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FSPKF:
- Fisher & Paykel Healthcare Unveils F&P Nova Nasal Mask in New Zealand and Australia
- Fisher & Paykel Healthcare Announces Share Transfer to VP
- Fisher & Paykel Healthcare Expands Auckland Campus with New Building
- Hyperion Asset Management Reduces Stake in Fisher & Paykel Healthcare
- Mitsubishi UFJ Reduces Stake in Fisher & Paykel Healthcare